Fantastic 454: Biotech Unveils Rapid Genome Sequencing Platform


By Kevin Davies Bio-IT World

In a dramatic advance for alternative DNA sequencing technologies, scientists at 454 Life Sciences Corp. have essentially sequenced and assembled a complete bacterial genome sequence based on a mere 4-hour run on the company’s proprietary instrument.

08-01-05-news-454-dna-instrument 
454 Life Sciences' DNA sequencing
system.
 
The analysis of some 25 million bases of DNA sequence using 454’s “sequencing by synthesis” nanotechnology approach allowed a team of more than 50 researchers to assemble almost the complete genome of Mycoplasma genitalium – some 580,000 nucleotides, or bases – with greater than 99 percent accuracy. The group, reporting in the online edition of Nature, claims a 100-fold increase in efficiency over conventional sequencing methods.

“This paper struck me as approaching one of the quantum leaps the National Human Genome Research Institute asked for in its vision for the future of genome research a few years ago,” says Nature senior editor Chris Gunter. “We all acknowledge that there needs to be cheaper, faster sequencing, and here's the first new technology since Sanger sequencing.”

“It’s completely analogous to personal computers displacing mainframes,” enthuses 454 founder and chairman, Jonathan Rothberg. “Now, anyone can have their own genome center. If you can miniaturize something, then everything gets cheaper and faster.”

Chemical Reaction
DNA sequencing chemistry has hardly changed since the establishment of the dideoxy sequencing method by Nobel laureate Fred Sanger and colleagues in Cambridge, England, back in 1977. Advances in automation from Applied Biosystems and other companies have permitted rapid improvements in sequence throughput and affordability, culminating in the completion of the Human Genome Project. But in recent years, companies such as Solexa, Helicos, and 454 have been developing new approaches that rely heavily on computer algorithms to virtually assemble hundreds of thousands of relatively short (about 100 bases) DNA fragments to produce the final sequence.

The genesis of 454 can be traced back to 1999, when Rothberg’s newborn son was rushed to hospital. The founder of CuraGen was left pondering what it would take to develop a new approach to DNA sequencing that could provide personalized genome information. He spun off 454 Life Sciences from CuraGen the following year.

454’s instruments – costing $500,000 apiece – are currently being tested at the Broad Institute, the J. Craig Venter Institute Joint Technology Center, the Wellcome Trust Sanger Institute, and other leading sequencing centers. The results in the Nature article explain why the new platform has aroused such intense interest.

The 454 approach involves shearing the starting material DNA using a nebulizer. Rothberg explains: “[We] nebulize the DNA into little fragments, shake it in oil and water, so each DNA fragment goes into a separate water droplet. So instead of bacteria, we separate the DNA into drops. Then we do PCR, so every drop has 10 million copies. Then we put in a bead, drive the DNA to the bead, so instead of the cloning and robots, one person can prepare any genome.”

The DNA-covered beads are loaded into the microscopic hexagonal wells of a fiber-optic slide, which contains about 1.6 million wells. In 454’s benchtop instrument, chemicals and reagents flow over the beads in the wells. Solutions containing each nucleotide are applied in a repetitive cycle, in the order T-C-A-G. Excess reagent is washed away using a nuclease, before a fresh solution is applied. This cycle is repeated dozens of times. 

As each base is incorporated into the DNA fragments on each bead, pyrophosphate is released, generating photons that are detected in quantitative fashion by a CCD (charge-coupled device) sensor on the base of the slide. Runs of a single base, e.g. A-A-A-A show up as four times the intensity of a single nucleotide position.

The 454 Protocol
Rothberg and colleagues detail in the Nature article the process for resequencing the genome of M. genitalium. After one person prepares the beaded DNA fragments on the fiber-optic slide (about 6 hours), the automated sequencing by synthesis reactions (42 T-C-A-G cycles) takes just four hours. With an average read length of 110 bases and 40-fold sequence coverage, and correcting for accuracy, the researchers covered 96.5 percent of the bacterial genome with 99.96-percent accuracy from a single instrument run.

“The referees felt that the improvement in sequencing technology was very important and would make big strides in the field, to the point of changing how sequencing centers are set up and run,” says Nature’s Gunter. “You know you have a good paper when it's in the review process and people unconnected to the paper approach you at meetings and say, ‘Oh, I heard you have that paper -- it's really exciting!’ And that's what happened with this one.”

The 454 authors concede that there are still key improvements to be made in read length and accuracy. While the average read is 100 bases, the instrument has been able to produce accurate runs of 200 bases, and occasionally even 400 bases. The accuracy with genomic DNA samples is lower than for test fragments, but that is attributed to problems with the templates, not the sequencing technology per se. And the accuracy of individual sequence reads relies on replication and redundancy to match that of more traditional Sanger methods.

Noting parallels with Moore’s Law, the authors conclude: “Future increases in throughput, and a concomitant reduction in cost per base, may come from the continued miniaturization of the fibre-optic reactors, allowing more sequence to be produced per unit area – a scaling characteristic similar to that which enabled the prediction of significant improvements in the integrated circuit at the start of its development cycle.”

There are 56 co-authors on the Nature article, all but three from 454, based in Branford, Conn. Among the other contributors is Gene Myers, the Berkeley geneticist who headed the algorithm assembly team at Celera Genomics.

Margulies, M. et al. “Genome sequencing in microfabricated high-density picolitre reactors.” Nature. Doi:10.1038/nature03959

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Waters white paper image
Software Helps Doping Control Lab Streamline Results Management
Sponsored by Waters
The Karolinska University Hospital’s Doping Control Lab tests thousands of samples annually for stimulants, diuretics, and other masking agents. Increased regulatory pressure and new technologies increased the number of samples analyzed creating data management challenges. Waters® NuGenesis® Scientific Data Management System and TargetLynx™ Application Manager software were used to reduce the time required to calculate, review and search results.


sas whitepaper92
Managed Innovation, Assured Compliance
Sponsored by SAS
Discovery organizations are identifying a lot of promising compounds, but clinical research processes haven't kept pace with timely testing of all those potential therapies. This white paper describes how SAS® Drug Development supports true innovation across the clinical trial process.

In this white paper you will learn how to:

  • Assemble data to foster better collaboration
  • Get up-to-date information during clinical trials
  • Make informed decisions earlier in the trial process


BlueArc white paper image
Addressing Life Sciences Constantly Growing Data Challenges Research Environments
Sponsored by BlueArc
The continued explosion of raw experimental data, the increased use of video, the growing adoption of new data retention practices, and the move to high throughput computational workflows are all placing new demands on the way life sciences organizations store and manage their data.

Download this white paper to learn about:

  • Factors driving the data explosion in the life sciences
  • New data management issues that must be addressed
  • HPC trends that are placing new demands on storage
  • Storage solution attributes that address performance, manageability, and energy efficiency.


Life Science Webcasts & Podcasts

Medidata Solutions

Rising Clinical Trial Delays and Costs - Addressing the Cause, Not the Symptoms 

medidata podcastProtocol complexity is taking a toll on clinical study speed and efficiency: increasingly complicated and ambitious protocols are not only burdening sites and study volunteers but are also prolonging trials and increasing expenses. In response, sponsors have turned to global study placement, restructured site relationships and new site management practices, but the problem remains.

This podcast will discuss:

  • Why these responses address only the symptoms, not the underlying cause, of rising clinical trial delays and costs.
  • Results of a recent joint Tufts University / Medidata Solutions study.
  • New metrics benchmarking protocol design trends.
  • Systematic protocol design improvements and why they are essential to clinical trial performance excellence.

Speakers: Ken Getz, Senior Research Fellow at the Tufts Center for the Study of Drug Development, and Ed Seguine, General Manager, Trial Planning Solutions at Medidata.

Download Now 



More Podcasts

Job Openings

Director, Center For Information Technology (CIT) - National Institutes of Health  (NIH), Department of Health and Human Service
Located in Bethesda, MD. This position requires:
• High-level vision, leadership, management, and modernization of CIT programs and services.
• Strategic direction and policy development for CIT long-term operations and objectives.
• Serve as a key IT advisor to the NIH Chief Information Officer.
A TOP SECRET security clearance will be required.  More job detail is found at:  http://www.jobs.nih.gov under the Executive Jobs section.Or contact Ms.Winnie Garner at seniorre@od.nih.gov.  Applications must be received ELECTRONICALLY by (11:59 p.m.), December 17, 2008.  DHHS and NIH are Equal Opportunity Employers

Bioinformatics Manager- Lilly Singapore Centre for Drug Discovery
For more information click here 

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.